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Introduction
Rapamycin represents substantial progress as a main-
tenance immunosuppressive agent to prevent rejection
episodes and to decrease steroid and calcineurin
inhibitor (CNI) exposure [1–3]. This drug is com-
monly administered in combination with mycophenol-
ate mofetil, an inhibitor of inosine monophosphate
dehydrogenase, or with azathioprine, a purine anti-
metabolite. Furthermore, rapamycin is prescribed as
a substitute for or in combination with CNI.
The macrocyclic lactone rapamycin or sirolimus
(Rapamune) and its more polar derivative ever-
olimus (Certican) exhibit a similar mode of action
but a different pharmacokinetic behaviour. Everolimus
shows a shorter elimination half-life (30 vs 60 h) and
a higher bioavailability [4,5].
In the absence of concomitant use of CNI,
rapamycin was shown repeatedly to spare renal
function. To the surprise of the transplant community,
evidence for rapamycin-associated nephrotoxicity has
been accumulating in the last few years. In line with
such observations, Crew et al. [6] describe two patients
with thrombotic microangiopathy as a result of
rapamycin exposure and suggest potential mechanisms
of the disorder in this edition of NDT. Thus, deﬁnitely,
the question has to be addressed whether nephrotoxi-
city of rapamycin represents a relevant problem in
clinical practice.
Evidence of rapamycin nephrotoxicity
in kidney transplantation
Randomized phase-III trials (US trial and global trial)
conducted over 24 months and comprising almost
1300 renal allograft recipients treated with cyclosporin
investigated the efﬁcacy and safety of the concurrent
administration of sirolimus in doses of 2 or 5mg/day vs
placebo or azathioprine [7]. Mean values of serum
creatinine concentrations in patients treated with
sirolimus were higher than in subjects treated with
placebo or azathioprine (175 vs 137 mmol/l) [7]. The
addition of sirolimus revealed a pharmacokinetic
interaction, since 20% lower doses of cyclosporin
were required to achieve target levels in patients
treated with cyclosporin and rapamycin than in
patients exposed to cyclosporin plus azathioprine or
placebo. Nevertheless, the 1 year graft survival rates in
patients on rapamycin were similar and the rejection
rates lower, suggesting nephrotoxicity of rapamycin
rather than under-immunosuppression.
In a prospective study, high-risk renal allograft
recipients (79% African-Americans, 59% delayed graft
function, high proportion of marginal kidneys) were
randomized to receive, following thymoglobulin induc-
tion, either standard tacrolimus (10–15 ng/ml) plus
reduced sirolimus (5–10 ng/ml; group I, n¼ 16)
or reduced tacrolimus (5–10 ng/ml) plus standard
sirolimus (10–15 ng/ml; group II, n¼ 23) [8]. Although
the outcome at 6 months was identical between the two
groups, 38% of patients from group I needed
discontinuation of tacrolimus due to biopsy-proven
tacrolimus nephrotoxicity. Therefore, a reduced qual-
ity of the grafts may render them more susceptible to
nephrotoxicity of this drug combination.
Furthermore, two cases of acute oliguric renal
allograft failure due to suspected acute tubular necro-
sis (one case biopsy-conﬁrmed) associated with the
combined use of tacrolimus and sirolimus were
described [9].
In a recent retrospective analysis, the inﬂuence of
immunosuppression on delayed graft function (DGF)
was investigated in 144 kidney transplant patients
treated with tacrolimus with or without rapamycin [1].
DGF occurred almost three times more often in
subjects treated with rapamycin than without (25%
vs 8.9%), and was correlated positively with drug dose
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(odds ratio: 1.1 per mg). In addition, a subset of
rapamycin-treated patients developed cast nephrop-
athy, reminiscent of myeloma cast nephropathy. These
observations are in line with the results from another
retrospective clinical study examining 132 renal allo-
graft recipients who developed DFG (23.4%) from a
total of 563 adults [10]. Recipients of sirolimus were
half as likely to resolve DGF or twice as likely to
remain on dialysis as subjects without this agent [10].
In a recent 12 month analysis of 634 cyclosporin-
treated heart transplant patients, the concurrent
administration of everolimus and cyclosporin led to a
signiﬁcant increase in serum creatinine levels beginning
on day 28, as compared with the use of azathioprine
[11]. Importantly, cyclosporin drug concentrations
were not different among the different groups.
Thus, in patients with an allograft, the combina-
tion of a CNI (cyclosporine) and sirolimus/everolimus
is deﬁnitely associated with higher serum creatinine
concentrations than a CNI combined with the other
immunosuppressive agents.
Nephrotoxicity of rapamycin
in glomerulonephritis
Reports of rapamycin-associated nephrotoxicity in
native kidneys are sparse due to its preferential use
in transplantation medicine. The largest clinical study
included 11 patients suffering from chronic glomer-
ulonephritis (GN) with moderate kidney failure and
proteinuria (1 g/day) [12]. Within the ﬁrst 6 weeks of
rapamycin therapy (5mg/day), six subjects developed
acute kidney failure with improvement of kidney
function after discontinuation of rapamycin in ﬁve
cases. However, no biopsies were performed in these
patients and the mechanism of rapamycin-associated
nephrotoxicity remained unclear.
In addition, a recent investigation described four
patients with chronic allograft dysfunction who devel-
oped biopsy-conﬁrmed post-transplantation GN with
nephrotic-range proteinuria 2–9 months after conver-
sion of a CNI-containing regimen to rapamycin [13].
Stabilization of kidney function and complete remis-
sion of proteinuria occurred in all cases after reintro-
duction of CNI.
Mechanisms of rapamycin-associated
nephrotoxicity
Rapamycin may display direct tubular or, to a lesser
degree, glomerular toxicity and may also potentiate
CNI nephrotoxicity.
Sirolimus and everolimus bind to FKBP12 and
inhibit mTOR, later identiﬁed as FRAP kinase [4],
a key regulator of cell proliferation, growth, apoptosis
and survival in response to growth factors and cyto-
kines [1,4,14]. FRAP kinase belongs to the phospha-
tidylinositol kinases, crucial for the progression of the
cell cycle from G1 to S phase by signalling through the
p70 S6 kinase and eIF4E-binding protein [4].
Rapamycin exposure leads primarily to cell-cycle
arrest in the early G1 phase of T and B lymphocytes
[4,10]. Following transplantation, rapamycin prevents
acute rejection by inhibition of cytokine and growth
factor-mediated lymphocyte proliferation, especially
the proliferation and clonal expansion of interleukin-
2-stimulated T lymphocytes [15]. Importantly, other
cells are also a direct target of this drug, includ-
ing endothelial, smooth muscle, mesangial and renal
tubular cells [1,12,16]. Furthermore, rapamycin may
promote the ‘default way’ of apoptosis by inhibiting
the activity of ‘survival factors’ and of p70 S6 kinase
[15,17].
Importantly, rapamycin inhibits growth factor-
induced proliferation of cultured proximal tubular cells
and supports their apoptosis by blocking the survival
effects of the same growth factors [15]. Accordingly,
rapamycin impaired recovery from experimental acute
renal failure induced by renal artery occlusion due to
the combined effects of increased tubular cell loss
(apoptosis) and inhibition of regenerative proliferation
[15]. These effects were attributable to the inhibition of
p70 S6 kinase [15].
In addition, rats given rapamycin (3 mg/kg/p.o.) for
2 weeks on a low-salt diet developed magnesium wast-
ing and structural renal lesions consisting of tubular
collapse, vacuolization and nephrocalcinosis [18].
Thus, during periods of renal allograft injury,
rapamycin may be harmful due to its negative effects
on tubular cell regeneration and survival [1,15].
The same may be true at the glomerular level in
inﬂammatory states that require intact cell prolifera-
tion for repair and/or compensatory mechanisms [12].
In addition, rapamycin may potentiate tubular toxicity
of proteinuria per se [12].
Toxicity of rapamycin, indeed, depends upon the
type of GN, as ﬁrst reported by our group in experi-
mental GN models [19]. We demonstrated that
everolimus highly accentuated acute mesangial prolif-
erative anti-Thy1.1 nephritis, reﬂected by severe
glomerular destruction with areas of necrosis, kidney
failure and increased proteinuria. In contrast, a signiﬁ-
cant reduction of proteinuria was achieved as a result
of everolimus exposure in the non-proliferative acute
puromycin aminonucleoside nephrosis [19]. In addition
to the antiproliferative effect, everolimus also inhibits
mesangial cell migration, mediated by preventing the
decrease in the CDK-inhibitor p27 KIP1 induced by
growth factors [20]. In this respect, particular caution
may be warranted for the use of rapamycin in
antibody-mediated forms of proliferative GN.
Pharmacokinetic and possibly also pharmacody-
namic interactions of CNI and sirolimus are another
potential mechanism of nephrotoxicity. Because of
the shared metabolism by the P-450 (CYP) 3A4 and
competition for the extrusion by the p-glycoprotein
mechanism, blood and tissue levels of both cyclosporin
and rapamycin can be increased if administered
concurrently [1,7,21–24]. Possibly, the same is true
for the tacrolimus and rapamycin combination
with respect to an intracellular accumulation resulting
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in direct tissue injury [1,8,12,25]. However, unlike
the cyclosporin/sirolimus combination, sirolimus/
tacrolimus pharmacokinetics appears to remain
essentially unchanged following their simultaneous
administration [23,24].
In addition, a possible potentiation of CNI nephro-
toxicity by sirolimus or everolimus per se unrelated
to changes in drug levels was proposed also [11]. This
may be especially true in cases of tissue regeneration
following injury.
Conclusions
Rapamycin and its derivative everolimus appear not to
be nephrotoxic to the healthy, predominantly quies-
cent kidney. However, in vitro studies and observations
in animals and humans indicate that these agents are
nephrotoxic in disease states. Evidence is growing that
the same mechanisms that lead to excellent immuno-
suppression may also impair recovery of tissue injury.
Therefore, the administration of rapamycin may
exacerbate pre-existing or newly occurring renal
lesions.
This might explain why renal function deteriorates
in patients with kidneys in the process of repairing
tubular cells (delayed graft function and acute tubular
necrosis), endothelial cells (thrombotic microangio-
pathy and GN) or mesangial cells (GN).
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